Kintara Therapeutics Inc

NASDAQ:KTRAUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.

Contact Information

Headquarters

9920 Pacific Heights Blvd Suite 150, Suite 200SAN DIEGO, CA, United States 92121

Phone

858-350-4364

Fax

604-202-1384

Executives

Chairman of the Board, President, Chief Executive Officer, Interim Chief Financial Officer

Robert Hoffman

Senior Vice President, Business Development

John Liatos

Independent Director

Tamara Favorito

Independent Director

Laura Johnson

Independent Director

Robert Toth